Navigation Links
New Treatment Discovered For Pediatric Cholera

Single dose of antibiotics may be used to treat childhood cholera.

Researchers in Bangladesh have found that severe cholera in children can be treated effectively with a single dose // of the antibiotic ciprofloxacin , according to a study published online by The Lancet.

Cholera is a major global health problem particularly in children in areas in less-developed countries. In the resource-limited countries where cholera occurs, any reduction in hospital stay is important as it reduces the demands on the healthcare system. Currently, WHO recommends a 3-day, 12-dose course of antibiotic treatment with either tetracycline or erythromycin for treatment of cholera in children.

Researchers from Center for Health and Population Research, Bangladesh had compared the effectiveness of a 3-day, 12-dose course of erythromycin with a single-dose of ciprofloxacin. 162 children were randomly assigned to treatment with either ciprofloxacin or erythromycin. Treatment with ciprofloxacin was successful within 48 hours in 60% of cases, compared with 55% in children who were treated with erythromycin. Ciprofloxacin was more effective than erythromycin at reducing vomiting and stool number and volume. However, single-dose ciprofloxacin was inferior to erythromycin in eradicating the cholera bacteria—Vibrio cholerae—resulting in those treated with ciprofloxacin excreting the bacteria for longer than those treated with erythromycin.

Dr Saha, the main author of the study, concludes: “For infections caused by susceptible strains of V cholerae, single-dose ciprofloxacin achieves clinical outcomes similar to or better than, those achieved with 12-dose erythromycin treatment in childhood cholera, but is less effective in eradicating Vcholeraefrom stool”

Source: The Lancet, Newswis
'"/>




Page: 1

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... ... December 06, 2016 , ... ... of a higher risk of serious health problems, such as cardiovascular illness, according ... Peiman Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that the ...
(Date:12/6/2016)... , ... December 06, 2016 , ... An inventor, from ... utilize a sling, so she invented the patent-pending SLING-VEST. , The SLING-VEST provides an ... offers an improved alternative to traditional slings. As a result, it helps to reduce ...
(Date:12/6/2016)... ... December 06, 2016 , ... Mount Sinai Health System today ... of Neurosurgery, where clinicians can confer and order 3D models for their cases. ... basis with quick turnaround times. This resource will be the first of its ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Touchpoint Solution’s new neuroscience wearable, ... Almost 200 backers pledged more than $25,000 on Kickstarter to bring ... Dr. Amy Serin, an Arizona Neuropsychologist and inventor, says she feels like she stumbled ...
(Date:12/6/2016)... ... December 06, 2016 , ... After 30 years ... Susan Glasgow has announced her retirement from HASA at the end ... more than 4,000 individuals and families with hearing and speech services. She has ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 2016 With opioids commonly used for pain management for ... market that has led to nationwide fatalities. The synthetic ... stronger than heroin or morphine, resulting in likelihood of addiction, abuse ... , , ... clinical operations, Behavioral Health for HMC HealthWorks, explained the opioid drug ...
(Date:12/6/2016)... -- Blueprint Medicines Corporation (NASDAQ: BPMC ), a ... patients with genomically defined diseases, today announced that it ... in shares of its common stock. In addition, Blueprint ... to purchase up to an additional of $18,750,000 million ... the public offering. All shares of common stock will ...
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 ... focused on the development of Conditionally Active ... BioAtla and Beijing Sinobioway Group Company, Limited ... programs for development.  The specific program candidates ... In March 2015, BioAtla and Sinobioway entered ...
Breaking Medicine Technology: